Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Thy-1 (CD90) promotes bone formation and protects against obesity.

Picke AK, Campbell GM, Blüher M, Krügel U, Schmidt FN, Tsourdi E, Winzer M, Rauner M, Vukicevic V, Busse B, Salbach-Hirsch J, Tuckermann JP, Simon JC, Anderegg U, Hofbauer LC, Saalbach A.

Sci Transl Med. 2018 Aug 8;10(453). pii: eaao6806. doi: 10.1126/scitranslmed.aao6806.

PMID:
30089635
2.

Differential effects of high-fat diet and exercise training on bone and energy metabolism.

Picke AK, Sylow L, Møller LLV, Kjøbsted R, Schmidt FN, Steejn MW, Salbach-Hirsch J, Hofbauer C, Blüher M, Saalbach A, Busse B, Rauner M, Hofbauer LC.

Bone. 2018 Jul 20;116:120-134. doi: 10.1016/j.bone.2018.07.015. [Epub ahead of print]

PMID:
30036679
3.

Immune Profiling of Polysaccharide Submicron Vesicles.

Toma CC, Aloisi A, Bordoni V, Di Corato R, Rauner M, Cuniberti G, Delogu LG, Rinaldi R.

Biomacromolecules. 2018 Aug 13;19(8):3560-3571. doi: 10.1021/acs.biomac.8b00832. Epub 2018 Jul 27.

PMID:
30008208
4.

Role of WNT5A receptors FZD5 and RYK in prostate cancer cells.

Thiele S, Zimmer A, Göbel A, Rachner TD, Rother S, Fuessel S, Froehner M, Wirth MP, Muders MH, Baretton GB, Jakob F, Rauner M, Hofbauer LC.

Oncotarget. 2018 Jun 5;9(43):27293-27304. doi: 10.18632/oncotarget.25551. eCollection 2018 Jun 5.

5.

Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro and in vivo.

Hildebrandt S, Baschant U, Thiele S, Tuckermann J, Hofbauer LC, Rauner M.

Sci Rep. 2018 Jun 7;8(1):8711. doi: 10.1038/s41598-018-26300-z.

6.

Postnatal Skeletal Deletion of Dickkopf-1 Increases Bone Formation and Bone Volume in Male and Female Mice, Despite Increased Sclerostin Expression.

Colditz J, Thiele S, Baschant U, Niehrs C, Bonewald LF, Hofbauer LC, Rauner M.

J Bone Miner Res. 2018 May 7. doi: 10.1002/jbmr.3463. [Epub ahead of print]

PMID:
29734465
7.

[Osteoimmunology-IMMUNOBONE : Regulation of bone by inflammation].

Rauner M, Buttgereit F, Distler J, Garbe AI, Herrmann M, Hofbauer L, Hoffmann M, Jessberger R, Kornak U, Krönke G, Mundlos S, Spies C, Tuckermann J, Zwerina J.

Z Rheumatol. 2018 May;77(Suppl 1):12-15. doi: 10.1007/s00393-018-0455-0. Review. German. No abstract available.

PMID:
29691689
8.

Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway.

Balaian E, Wobus M, Weidner H, Baschant U, Stiehler M, Ehninger G, Bornhäuser M, Hofbauer LC, Rauner M, Platzbecker U.

Haematologica. 2018 Jan;103(1):61-68. doi: 10.3324/haematol.2017.172726. Epub 2017 Oct 27.

9.

Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism.

Tsourdi E, Lademann F, Ominsky MS, Rijntjes E, Köhrle J, Misof BM, Roschger P, Klaushofer K, Hofbauer LC, Rauner M.

Endocrinology. 2017 Nov 1;158(11):3765-3777. doi: 10.1210/en.2017-00247.

PMID:
28973221
10.

Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer.

Browne AJ, Kubasch ML, Göbel A, Hadji P, Chen D, Rauner M, Stölzel F, Hofbauer LC, Rachner TD.

Breast Cancer Res. 2017 Aug 9;19(1):92. doi: 10.1186/s13058-017-0885-7.

11.

Immune Suppressive and Bone Inhibitory Effects of Prednisolone in Growing and Regenerating Zebrafish Tissues.

Geurtzen K, Vernet A, Freidin A, Rauner M, Hofbauer LC, Schneider JE, Brand M, Knopf F.

J Bone Miner Res. 2017 Dec;32(12):2476-2488. doi: 10.1002/jbmr.3231. Epub 2017 Sep 13.

PMID:
28771888
12.

Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.

Göbel A, Kuhlmann JD, Link T, Wimberger P, Browne AJ, Rauner M, Hofbauer LC, Rachner TD.

Breast Cancer Res Treat. 2017 Aug;164(3):737-743. doi: 10.1007/s10549-017-4296-3. Epub 2017 May 19.

PMID:
28526959
13.

Loss of menin in osteoblast lineage affects osteocyte-osteoclast crosstalk causing osteoporosis.

Liu P, Lee S, Knoll J, Rauch A, Ostermay S, Luther J, Malkusch N, Lerner UH, Zaiss MM, Neven M, Wittig R, Rauner M, David JP, Bertolino P, Zhang CX, Tuckermann JP.

Cell Death Differ. 2017 Apr;24(4):672-682. doi: 10.1038/cdd.2016.165. Epub 2017 Jan 20.

14.

Myelodysplastic syndromes and bone loss in mice and men.

Weidner H, Rauner M, Trautmann F, Schmitt J, Balaian E, Mies A, Helas S, Baschant U, Khandanpour C, Bornhäuser M, Hofbauer LC, Platzbecker U.

Leukemia. 2017 Apr;31(4):1003-1007. doi: 10.1038/leu.2017.7. Epub 2017 Jan 11. No abstract available.

PMID:
28074069
15.

Bone Formation and the Wnt Signaling Pathway.

Rauner M, Rachner TD, Hofbauer LC.

N Engl J Med. 2016 Nov 10;375(19):1902. doi: 10.1056/NEJMc1609768. No abstract available.

PMID:
27959644
16.

Sclerostin Blockade-A Dual Mode of Action After All?

Baschant U, Henneicke H, Hofbauer LC, Rauner M.

J Bone Miner Res. 2016 Oct;31(10):1787-1790. doi: 10.1002/jbmr.2988. Epub 2016 Sep 14. No abstract available.

17.

Increased EPO Levels Are Associated With Bone Loss in Mice Lacking PHD2 in EPO-Producing Cells.

Rauner M, Franke K, Murray M, Singh RP, Hiram-Bab S, Platzbecker U, Gassmann M, Socolovsky M, Neumann D, Gabet Y, Chavakis T, Hofbauer LC, Wielockx B.

J Bone Miner Res. 2016 Oct;31(10):1877-1887. doi: 10.1002/jbmr.2857. Epub 2016 May 13.

18.

Role of milk fat globule-epidermal growth factor 8 in osteoimmunology.

Sinningen K, Thiele S, Hofbauer LC, Rauner M.

Bonekey Rep. 2016 Jul 20;5:820. doi: 10.1038/bonekey.2016.52. eCollection 2016. Review.

19.

Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors.

Baschant U, Rauner M, Balaian E, Weidner H, Roetto A, Platzbecker U, Hofbauer LC.

Haematologica. 2016 Dec;101(12):1499-1507. Epub 2016 Aug 18.

20.

Effects of insulin therapy on porosity, non-enzymatic glycation and mechanical competence in the bone of rats with type 2 diabetes mellitus.

Campbell GM, Tiwari S, Picke AK, Hofbauer C, Rauner M, Morlock MM, Hofbauer LC, Glüer CC.

Bone. 2016 Oct;91:186-93. doi: 10.1016/j.bone.2016.08.003. Epub 2016 Aug 4.

PMID:
27497735
21.

WNT5A and Its Receptors in the Bone-Cancer Dialogue.

Thiele S, Rachner TD, Rauner M, Hofbauer LC.

J Bone Miner Res. 2016 Aug;31(8):1488-96. doi: 10.1002/jbmr.2899. Review.

22.

Sulfated hyaluronan improves bone regeneration of diabetic rats by binding sclerostin and enhancing osteoblast function.

Picke AK, Salbach-Hirsch J, Hintze V, Rother S, Rauner M, Kascholke C, Möller S, Bernhardt R, Rammelt S, Pisabarro MT, Ruiz-Gómez G, Schnabelrauch M, Schulz-Siegmund M, Hacker MC, Scharnweber D, Hofbauer C, Hofbauer LC.

Biomaterials. 2016 Jul;96:11-23. doi: 10.1016/j.biomaterials.2016.04.013. Epub 2016 Apr 21.

PMID:
27131598
23.

Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.

Göbel A, Thiele S, Browne AJ, Rauner M, Zinna VM, Hofbauer LC, Rachner TD.

Cancer Lett. 2016 May 28;375(1):162-171. doi: 10.1016/j.canlet.2016.03.004. Epub 2016 Mar 8.

PMID:
26968247
24.

p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells.

Browne AJ, Göbel A, Thiele S, Hofbauer LC, Rauner M, Rachner TD.

Cell Death Dis. 2016 Feb 25;7:e2119. doi: 10.1038/cddis.2016.32.

25.

RANKL/OPG in Breast Cancer - Extending Its Territory to BRCA Mutation Carriers.

Rachner TD, Rauner M.

EBioMedicine. 2015 Sep 24;2(10):1270-1. doi: 10.1016/j.ebiom.2015.09.035. eCollection 2015 Oct. No abstract available.

26.

Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins.

Göbel A, Browne AJ, Thiele S, Rauner M, Hofbauer LC, Rachner TD.

Breast Cancer Res Treat. 2015 Dec;154(3):623-31. doi: 10.1007/s10549-015-3624-8. Epub 2015 Oct 29.

PMID:
26515701
27.

P38 regulates the Wnt inhibitor Dickkopf-1 in breast cancer.

Rachner TD, Göbel A, Browne A, Hötzel J, Rauner M, Hofbauer LC.

Biochem Biophys Res Commun. 2015 Oct 30;466(4):728-32. doi: 10.1016/j.bbrc.2015.09.101. Epub 2015 Sep 25.

PMID:
26407843
28.

Milk Fat Globule-Epidermal Growth Factor 8 (MFG-E8) Is a Novel Anti-inflammatory Factor in Rheumatoid Arthritis in Mice and Humans.

Albus E, Sinningen K, Winzer M, Thiele S, Baschant U, Hannemann A, Fantana J, Tausche AK, Wallaschofski H, Nauck M, Völzke H, Grossklaus S, Chavakis T, Udey MC, Hofbauer LC, Rauner M.

J Bone Miner Res. 2016 Mar;31(3):596-605. doi: 10.1002/jbmr.2721. Epub 2015 Nov 9.

29.

[Prevention of Occupational Injuries Related to Hands: Calculation of Subsequent Injury Costs for the Austrian Social Occupational Insurance Institution (AUVA)].

Rauner MS, Mayer B, Schaffhauser-Linzatti MM.

Handchir Mikrochir Plast Chir. 2015 Aug;47(4):228-34. doi: 10.1055/s-0035-1550044. Epub 2015 Aug 19. German.

PMID:
26287325
30.

Thyrotropin serum levels are differentially associated with biochemical markers of bone turnover and stiffness in women and men: results from the SHIP cohorts.

Tsourdi E, Wallaschofski H, Rauner M, Nauck M, Pietzner M, Rettig R, Ittermann T, Völzke H, Völker U, Hofbauer LC, Hannemann A.

Osteoporos Int. 2016 Feb;27(2):719-27. doi: 10.1007/s00198-015-3276-x. Epub 2015 Aug 12.

PMID:
26264603
31.

Structural and functional insights into sclerostin-glycosaminoglycan interactions in bone.

Salbach-Hirsch J, Samsonov SA, Hintze V, Hofbauer C, Picke AK, Rauner M, Gehrcke JP, Moeller S, Schnabelrauch M, Scharnweber D, Pisabarro MT, Hofbauer LC.

Biomaterials. 2015 Oct;67:335-45. doi: 10.1016/j.biomaterials.2015.07.021. Epub 2015 Jul 15.

PMID:
26232882
32.

Hyperthyroidism and Hypothyroidism in Male Mice and Their Effects on Bone Mass, Bone Turnover, and the Wnt Inhibitors Sclerostin and Dickkopf-1.

Tsourdi E, Rijntjes E, Köhrle J, Hofbauer LC, Rauner M.

Endocrinology. 2015 Oct;156(10):3517-27. doi: 10.1210/en.2015-1073. Epub 2015 Jul 28.

PMID:
26218891
33.

Acute phase serum amyloid A induces proinflammatory cytokines and mineralization via toll-like receptor 4 in mesenchymal stem cells.

Ebert R, Benisch P, Krug M, Zeck S, Meißner-Weigl J, Steinert A, Rauner M, Hofbauer L, Jakob F.

Stem Cell Res. 2015 Jul;15(1):231-9. doi: 10.1016/j.scr.2015.06.008. Epub 2015 Jun 23.

34.

Serum fetuin-A levels and abdominal aortic calcification in healthy men - The STRAMBO study.

Schoppet M, Rauner M, Benner J, Chapurlat R, Hofbauer LC, Szulc P.

Bone. 2015 Oct;79:196-202. doi: 10.1016/j.bone.2015.06.004. Epub 2015 Jun 12.

PMID:
26079998
35.

Bone defect regeneration and cortical bone parameters of type 2 diabetic rats are improved by insulin therapy.

Picke AK, Gordaliza Alaguero I, Campbell GM, Glüer CC, Salbach-Hirsch J, Rauner M, Hofbauer LC, Hofbauer C.

Bone. 2016 Jan;82:108-15. doi: 10.1016/j.bone.2015.06.001. Epub 2015 Jun 6.

PMID:
26055107
36.

Effects of parathyroid hormone on cortical porosity, non-enzymatic glycation and bone tissue mechanics in rats with type 2 diabetes mellitus.

Campbell GM, Tiwari S, Hofbauer C, Picke AK, Rauner M, Huber G, Peña JA, Damm T, Barkmann R, Morlock MM, Hofbauer LC, Glüer CC.

Bone. 2016 Jan;82:116-21. doi: 10.1016/j.bone.2015.04.049. Epub 2015 May 5.

PMID:
25952971
37.

The endocrine role of the skeleton.

Rauner M, Coudert A, Sobacchi C, Del Fattore A.

Int J Endocrinol. 2015;2015:265151. doi: 10.1155/2015/265151. Epub 2015 Apr 2. No abstract available.

38.

Loss of milk fat globule-epidermal growth factor 8 (MFG-E8) in mice leads to low bone mass and accelerates ovariectomy-associated bone loss by increasing osteoclastogenesis.

Sinningen K, Albus E, Thiele S, Grossklaus S, Kurth T, Udey MC, Chavakis T, Hofbauer LC, Rauner M.

Bone. 2015 Jul;76:107-14. doi: 10.1016/j.bone.2015.04.003. Epub 2015 Apr 11.

PMID:
25868798
39.

Loss of bone strength in HLA-B27 transgenic rats is characterized by a high bone turnover and is mainly osteoclast-driven.

Rauner M, Thiele S, Fert I, Araujo LM, Layh-Schmitt G, Colbert RA, Hofbauer C, Bernhardt R, Bürki A, Schwiedrzik J, Zysset PK, Pietschmann P, Taurog JD, Breban M, Hofbauer LC.

Bone. 2015 Jun;75:183-91. doi: 10.1016/j.bone.2015.02.024. Epub 2015 Mar 3.

PMID:
25746795
40.

Erythropoietin directly stimulates osteoclast precursors and induces bone loss.

Hiram-Bab S, Liron T, Deshet-Unger N, Mittelman M, Gassmann M, Rauner M, Franke K, Wielockx B, Neumann D, Gabet Y.

FASEB J. 2015 May;29(5):1890-900. doi: 10.1096/fj.14-259085. Epub 2015 Jan 28.

PMID:
25630969
41.

Graves' disease after treatment with alemtuzumab for multiple sclerosis.

Tsourdi E, Gruber M, Rauner M, Blankenburg J, Ziemssen T, Hofbauer LC.

Hormones (Athens). 2015 Jan-Mar;14(1):148-53. doi: 10.14310/horm.2002.1501.

42.

Myelodysplasia is in the niche: novel concepts and emerging therapies.

Bulycheva E, Rauner M, Medyouf H, Theurl I, Bornhäuser M, Hofbauer LC, Platzbecker U.

Leukemia. 2015 Feb;29(2):259-68. doi: 10.1038/leu.2014.325. Epub 2014 Nov 14. Review.

43.

WNT5A has anti-prostate cancer effects in vitro and reduces tumor growth in the skeleton in vivo.

Thiele S, Göbel A, Rachner TD, Fuessel S, Froehner M, Muders MH, Baretton GB, Bernhardt R, Jakob F, Glüer CC, Bornhäuser M, Rauner M, Hofbauer LC.

J Bone Miner Res. 2015 Mar;30(3):471-80. doi: 10.1002/jbmr.2362.

44.

High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients.

Rachner TD, Thiele S, Göbel A, Browne A, Fuessel S, Erdmann K, Wirth MP, Fröhner M, Todenhöfer T, Muders MH, Kieslinger M, Rauner M, Hofbauer LC.

BMC Cancer. 2014 Sep 2;14:649. doi: 10.1186/1471-2407-14-649.

45.

Instructions for producing a mouse model of glucocorticoid-induced osteoporosis.

Thiele S, Baschant U, Rauch A, Rauner M.

Bonekey Rep. 2014 Jul 2;3:552. doi: 10.1038/bonekey.2014.47. eCollection 2014.

46.

Artificial extracellular matrices with oversulfated glycosaminoglycan derivatives promote the differentiation of osteoblast-precursor cells and premature osteoblasts.

Hempel U, Preissler C, Vogel S, Möller S, Hintze V, Becher J, Schnabelrauch M, Rauner M, Hofbauer LC, Dieter P.

Biomed Res Int. 2014;2014:938368. doi: 10.1155/2014/938368. Epub 2014 Apr 28.

47.

Cathepsin S controls adipocytic and osteoblastic differentiation, bone turnover, and bone microarchitecture.

Rauner M, Föger-Samwald U, Kurz MF, Brünner-Kubath C, Schamall D, Kapfenberger A, Varga P, Kudlacek S, Wutzl A, Höger H, Zysset PK, Shi GP, Hofbauer LC, Sipos W, Pietschmann P.

Bone. 2014 Jul;64:281-7. doi: 10.1016/j.bone.2014.04.022. Epub 2014 Apr 26.

PMID:
24780878
48.

Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells.

Wilke M, Göbel A, Rauner M, Benad-Mehner P, Schütze N, Füssel S, Hadji P, Hofbauer LC, Rachner TD.

J Bone Oncol. 2014 Feb 18;3(1):10-7. doi: 10.1016/j.jbo.2014.02.001. eCollection 2014 Mar.

49.

Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin.

Benad-Mehner P, Thiele S, Rachner TD, Göbel A, Rauner M, Hofbauer LC.

J Bone Oncol. 2013 Nov 15;3(1):18-24. doi: 10.1016/j.jbo.2013.11.001. eCollection 2014 Mar.

50.

Dickkopf-1 is regulated by the mevalonate pathway in breast cancer.

Rachner TD, Göbel A, Thiele S, Rauner M, Benad-Mehner P, Hadji P, Bauer T, Muders MH, Baretton GB, Jakob F, Ebert R, Bornhäuser M, Schem C, Hofbauer LC.

Breast Cancer Res. 2014 Feb 14;16(1):R20. doi: 10.1186/bcr3616.

Supplemental Content

Loading ...
Support Center